"Researchers have suspected that MDS is a stem cell disease and now we finally have proof," said co-senior author Amit Verma, M.B.B.S. Dr. Verman is associate professor of medicine and developmental and molecular biology at Einstein and a physician at Montefiore Einstein Center for Cancer Care.
You are here
Coverage of the latest news and updates from the field of stem cells.
PBC is a chronic, progressive disease that affects one in 1,000 women over the age of 40.
Cell therapies are traditionally delivered through intravenous (IV) injections for systemic effect.
The Neo-Urinary Conduit™ combines a patient's own cells and a bio-absorbable scaffold to regenerate a native-like urinary tissue conduit, transporting urine through a hole in the abdomen into a standard ostomy bag.
Prochymal is an intravenous formulation of mesenchymal stem cells (MSCs) derived from the bone marrow of healthy adult donors.
The general objective of the trials is to test the efficiency of stem cell therapy in detaining the autoimmune aggression of the disease in its initial phases.
NSI-189, the lead compound in Neuralstem's small molecule platform, is a proprietary chemical entity that stimulates new neuron growth in the hippocampus.
While stem cells show great promise for treating many medical conditions, tracking their migration and survival following transplantation in the body has been difficult.
"We are now dosing in both the lumbar and cervical regions of the spinal cord for the first time, where the stem cell therapy could support both walking and breathing," said Karl Johe, Ph.D., Neuralstem's chairman and chief scientific officer.